Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma

Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma

Adding panobinostat to bortezomib and dexamethasone did not significantly improve overall survival compared with bortezomib plus dexamethasone alone in patients with relapsed multiple myeloma, a study published in The Lancet Haematology has shown.1

The phase 3 PANORAMA 1 trial ( Identifier: NCT01023308) previously demonstrated that panobinostat plus bortezomib and dexamethasone significantly prolonged progression-free survival vs bortezomib and dexamethasone alone.

The final overall survival analysis of this trial has shown that median overall survival was 40.3 months (95% CI, 35.0-44.8) with panobinostat compared with 35.8 months (95% CI, 29.0-40.6) with placebo (hazard ratio [HR], 0.94; 95% CI, 0.78-1.14; P =.54), suggesting no significant difference between the 2 treatment arms.

Similarly, researchers found that among patients who had received at least 2 previous regimens including bortezomib and an immunomodulatory drug, median overall survival was 25.5 months (95% CI, 19.6-34.3) and 19.5 months (95% CI, 14.1-32.5) with panobinostat and placebo, respectively (HR, 1.01; 95% CI, 0.68-1.50).

The investigators hypothesize that optimizing this 3-drug regimen could potentially prolong treatment duration, thereby improving patient outcomes; however, further investigation would be needed to confirm this approach.

For the double-blind trial, investigators enrolled 768 patients with relapsed or relapsed and refractory multiple myeloma who had received 1 to 3 previous treatment regimens. Participants were randomly assigned 1:1 to receive panobinostat or placebo, in combination with bortezomib and dexamethasone.


1. San-Miguel JF, Hungria VT, Yoon S, et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Oct 14. doi: 10.1016/S2352-3026(16)30147-8. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs